GAP President on Donanemab Trial Results: Alzheimer’s Patients and Their Doctors May Have Another Disease-Modifying Therapy to Address this Disease
WASHINGTON, DC, May 3, 2023 — Following the announcement of Eli Lilly’s Phase 3 results on a study evaluating donanemab for the treatment of Alzheimer’s disease, Global Alzheimer’s Platform Foundation® (GAP) President John Dwyer said, “Today’s announcement is good news. After waiting nearly 20 years for a new treatment for Alzheimer’s, Alzheimer’s patients and their doctors […]